#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=2.
1-1	0-2	2.	_	_	_	_

#Text=The Role of the bHLH Proteins in Transcription
2-1	3-6	The	abstract[1]	new[1]	_	_
2-2	7-11	Role	abstract[1]	new[1]	_	_
2-3	12-14	of	abstract[1]	new[1]	_	_
2-4	15-18	the	abstract[1]|substance[3]	new[1]|new[3]	coref	6-11[0_3]
2-5	19-23	bHLH	abstract[1]|substance|substance[3]	new[1]|new|new[3]	coref	13-4
2-6	24-32	Proteins	abstract[1]|substance[3]	new[1]|new[3]	_	_
2-7	33-35	in	abstract[1]	new[1]	_	_
2-8	36-49	Transcription	abstract[1]|abstract	new[1]|new	coref	3-8

#Text=The regulation of genes expression by multiple transcription factors , cofactors and chromatin regulators
3-1	50-53	The	abstract[5]	new[5]	coref	5-1[14_5]
3-2	54-64	regulation	abstract[5]	new[5]	_	_
3-3	65-67	of	abstract[5]	new[5]	_	_
3-4	68-73	genes	abstract[5]|abstract|abstract[7]	new[5]|new|new[7]	coref	14-18[96_0]
3-5	74-84	expression	abstract[5]|abstract[7]	new[5]|new[7]	_	_
3-6	85-87	by	abstract[5]	new[5]	_	_
3-7	88-96	multiple	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-8	97-110	transcription	abstract[5]|abstract|abstract[9]	new[5]|giv|new[9]	coref	6-3
3-9	111-118	factors	abstract[5]|abstract[9]	new[5]|new[9]	_	_
3-10	119-120	,	abstract[5]	new[5]	_	_
3-11	121-130	cofactors	abstract[5]|abstract	new[5]|new	_	_
3-12	131-134	and	abstract[5]	new[5]	_	_
3-13	135-144	chromatin	abstract[5]|substance[11]	new[5]|new[11]	_	_
3-14	145-155	regulators	abstract[5]|substance[11]	new[5]|new[11]	_	_

#Text=establish and maintains a specific state of a cell .
4-1	156-165	establish	_	_	_	_
4-2	166-169	and	_	_	_	_
4-3	170-179	maintains	_	_	_	_
4-4	180-181	a	abstract[12]	new[12]	_	_
4-5	182-190	specific	abstract[12]	new[12]	_	_
4-6	191-196	state	abstract[12]	new[12]	_	_
4-7	197-199	of	abstract[12]	new[12]	_	_
4-8	200-201	a	abstract[12]|place[13]	new[12]|new[13]	coref	17-10[0_13]
4-9	202-206	cell	abstract[12]|place[13]	new[12]|new[13]	_	_
4-10	207-208	.	_	_	_	_

#Text=Inaccurate regulation of transmitted signals can results in diseases and severe disorders .
5-1	209-219	Inaccurate	abstract[14]	giv[14]	coref	10-12[52_14]
5-2	220-230	regulation	abstract[14]	giv[14]	_	_
5-3	231-233	of	abstract[14]	giv[14]	_	_
5-4	234-245	transmitted	abstract[14]|abstract[15]	giv[14]|new[15]	_	_
5-5	246-253	signals	abstract[14]|abstract[15]	giv[14]|new[15]	_	_
5-6	254-257	can	_	_	_	_
5-7	258-265	results	_	_	_	_
5-8	266-268	in	_	_	_	_
5-9	269-277	diseases	abstract	new	_	_
5-10	278-281	and	_	_	_	_
5-11	282-288	severe	abstract[17]	new[17]	_	_
5-12	289-298	disorders	abstract[17]	new[17]	_	_
5-13	299-300	.	_	_	_	_

#Text=Therefore , transcription requires balanced orchestration of adjustable complexes of proteins .
6-1	301-310	Therefore	_	_	_	_
6-2	311-312	,	_	_	_	_
6-3	313-326	transcription	abstract	giv	coref	7-5
6-4	327-335	requires	_	_	_	_
6-5	336-344	balanced	abstract[19]	new[19]	_	_
6-6	345-358	orchestration	abstract[19]	new[19]	_	_
6-7	359-361	of	abstract[19]	new[19]	_	_
6-8	362-372	adjustable	abstract[19]|object[20]	new[19]|new[20]	_	_
6-9	373-382	complexes	abstract[19]|object[20]	new[19]|new[20]	_	_
6-10	383-385	of	abstract[19]|object[20]	new[19]|new[20]	_	_
6-11	386-394	proteins	abstract[19]|object[20]|substance	new[19]|new[20]|giv	coref	12-1[76_0]
6-12	395-396	.	_	_	_	_

#Text=A key regulator of transcription is Mediator , a multi-subunit Mediator complex which interacts with RNA polymerase II ( Pol II ) , and coordinates the action of numerous co-activators and co-repressors .
7-1	397-398	A	abstract[22]	new[22]	coref	7-7[0_22]
7-2	399-402	key	abstract[22]	new[22]	_	_
7-3	403-412	regulator	abstract[22]	new[22]	_	_
7-4	413-415	of	abstract[22]	new[22]	_	_
7-5	416-429	transcription	abstract[22]|abstract	new[22]|giv	coref	10-12
7-6	430-432	is	_	_	_	_
7-7	433-441	Mediator	abstract	giv	appos	7-9[26_0]
7-8	442-443	,	_	_	_	_
7-9	444-445	a	abstract[26]	giv[26]	coref	10-4[49_26]
7-10	446-459	multi-subunit	abstract[26]	giv[26]	_	_
7-11	460-468	Mediator	person|abstract[26]	new|giv[26]	coref	8-3[34_0]
7-12	469-476	complex	abstract[26]	giv[26]	_	_
7-13	477-482	which	abstract[26]	giv[26]	_	_
7-14	483-492	interacts	abstract[26]	giv[26]	_	_
7-15	493-497	with	abstract[26]	giv[26]	_	_
7-16	498-501	RNA	abstract[26]|substance|substance[28]	giv[26]|new|new[28]	_	_
7-17	502-512	polymerase	abstract[26]|substance[28]	giv[26]|new[28]	_	_
7-18	513-515	II	abstract[26]|substance[28]	giv[26]|new[28]	_	_
7-19	516-517	(	abstract[26]	giv[26]	_	_
7-20	518-521	Pol	abstract[26]|person[29]	giv[26]|new[29]	coref	31-26[221_29]
7-21	522-524	II	abstract[26]|person[29]	giv[26]|new[29]	_	_
7-22	525-526	)	abstract[26]	giv[26]	_	_
7-23	527-528	,	abstract[26]	giv[26]	_	_
7-24	529-532	and	abstract[26]	giv[26]	_	_
7-25	533-544	coordinates	abstract[26]	giv[26]	_	_
7-26	545-548	the	abstract[26]|event[30]	giv[26]|new[30]	_	_
7-27	549-555	action	abstract[26]|event[30]	giv[26]|new[30]	_	_
7-28	556-558	of	abstract[26]|event[30]	giv[26]|new[30]	_	_
7-29	559-567	numerous	abstract[26]|event[30]|abstract[31]	giv[26]|new[30]|new[31]	_	_
7-30	568-581	co-activators	abstract[26]|event[30]|abstract[31]	giv[26]|new[30]|new[31]	_	_
7-31	582-585	and	abstract[26]|event[30]	giv[26]|new[30]	_	_
7-32	586-599	co-repressors	abstract[26]|event[30]|person	giv[26]|new[30]|new	_	_
7-33	600-601	.	_	_	_	_

#Text=Function of the Mediator is conserved in all eukaryotes , though , the individual subunits have diverged considerably in some organisms .
8-1	602-610	Function	abstract[33]	new[33]	_	_
8-2	611-613	of	abstract[33]	new[33]	_	_
8-3	614-617	the	abstract[33]|person[34]	new[33]|giv[34]	coref	9-15[43_34]
8-4	618-626	Mediator	abstract[33]|person[34]	new[33]|giv[34]	_	_
8-5	627-629	is	_	_	_	_
8-6	630-639	conserved	_	_	_	_
8-7	640-642	in	_	_	_	_
8-8	643-646	all	animal[35]	new[35]	_	_
8-9	647-657	eukaryotes	animal[35]	new[35]	_	_
8-10	658-659	,	_	_	_	_
8-11	660-666	though	_	_	_	_
8-12	667-668	,	_	_	_	_
8-13	669-672	the	abstract[36]	new[36]	coref	9-13[42_36]
8-14	673-683	individual	abstract[36]	new[36]	_	_
8-15	684-692	subunits	abstract[36]	new[36]	_	_
8-16	693-697	have	_	_	_	_
8-17	698-706	diverged	_	_	_	_
8-18	707-719	considerably	_	_	_	_
8-19	720-722	in	_	_	_	_
8-20	723-727	some	animal[37]	new[37]	_	_
8-21	728-737	organisms	animal[37]	new[37]	_	_
8-22	738-739	.	_	_	_	_

#Text=Up to date , for some bHLH family representatives , interactions with subunits of the Mediator and/or chromatin remodeling histone acetyltransferases/deacyltransferase , were reported .
9-1	740-742	Up	_	_	_	_
9-2	743-745	to	_	_	_	_
9-3	746-750	date	time	new	_	_
9-4	751-752	,	_	_	_	_
9-5	753-756	for	_	_	_	_
9-6	757-761	some	person[40]	new[40]	_	_
9-7	762-766	bHLH	person[40]	new[40]	_	_
9-8	767-773	family	abstract|person[40]	new|new[40]	coref	11-45[73_0]
9-9	774-789	representatives	person[40]	new[40]	_	_
9-10	790-791	,	_	_	_	_
9-11	792-804	interactions	event[41]	new[41]	_	_
9-12	805-809	with	event[41]	new[41]	_	_
9-13	810-818	subunits	event[41]|abstract[42]	new[41]|giv[42]	_	_
9-14	819-821	of	event[41]|abstract[42]	new[41]|giv[42]	_	_
9-15	822-825	the	event[41]|abstract[42]|person[43]	new[41]|giv[42]|giv[43]	coref	10-5[0_43]
9-16	826-834	Mediator	event[41]|abstract[42]|person[43]	new[41]|giv[42]|giv[43]	_	_
9-17	835-841	and/or	event[41]|abstract[42]	new[41]|giv[42]	_	_
9-18	842-851	chromatin	event[41]|abstract[42]|abstract[44]|substance[46]	new[41]|giv[42]|new[44]|new[46]	coref	24-27[177_44]
9-19	852-862	remodeling	event[41]|abstract[42]|abstract[44]|substance[46]	new[41]|giv[42]|new[44]|new[46]	_	_
9-20	863-870	histone	event[41]|abstract[42]|animal|substance[46]	new[41]|giv[42]|new|new[46]	coref	20-17
9-21	871-907	acetyltransferases/deacyltransferase	event[41]|abstract[42]|substance[46]	new[41]|giv[42]|new[46]	_	_
9-22	908-909	,	_	_	_	_
9-23	910-914	were	_	_	_	_
9-24	915-923	reported	_	_	_	_
9-25	924-925	.	_	_	_	_

#Text=In plants , the Mediator complex is a core element of transcription regulation important for their immunity .
10-1	926-928	In	_	_	_	_
10-2	929-935	plants	plant	new	ana	10-16
10-3	936-937	,	_	_	_	_
10-4	938-941	the	abstract[49]	giv[49]	coref	10-8[50_49]
10-5	942-950	Mediator	person|abstract[49]	giv|giv[49]	coref	11-28[66_0]
10-6	951-958	complex	abstract[49]	giv[49]	_	_
10-7	959-961	is	_	_	_	_
10-8	962-963	a	abstract[50]	giv[50]	coref	12-1[75_50]
10-9	964-968	core	abstract[50]	giv[50]	_	_
10-10	969-976	element	abstract[50]	giv[50]	_	_
10-11	977-979	of	abstract[50]	giv[50]	_	_
10-12	980-993	transcription	abstract[50]|abstract|abstract[52]	giv[50]|giv|giv[52]	coref	13-11
10-13	994-1004	regulation	abstract[50]|abstract[52]	giv[50]|giv[52]	_	_
10-14	1005-1014	important	abstract[50]|abstract[52]	giv[50]|giv[52]	_	_
10-15	1015-1018	for	_	_	_	_
10-16	1019-1024	their	plant|abstract[54]	giv|new[54]	ana	11-1[0_54]
10-17	1025-1033	immunity	abstract[54]	new[54]	_	_
10-18	1034-1035	.	_	_	_	_

#Text=It was shown , that in Arabidopsis thaliana important jasmonate signaling and resistance to fungus Botrytis cinerea , is dependent on the interaction between MED25 subunit of the Mediator and MYC2 , and interaction of MED8 subunit of the Mediator with FAMA belonging to the bHLH family .
11-1	1036-1038	It	abstract	giv	_	_
11-2	1039-1042	was	_	_	_	_
11-3	1043-1048	shown	_	_	_	_
11-4	1049-1050	,	_	_	_	_
11-5	1051-1055	that	_	_	_	_
11-6	1056-1058	in	_	_	_	_
11-7	1059-1070	Arabidopsis	abstract|plant[57]	new|new[57]	_	_
11-8	1071-1079	thaliana	plant[57]	new[57]	_	_
11-9	1080-1089	important	abstract[59]	new[59]	_	_
11-10	1090-1099	jasmonate	plant|abstract[59]	new|new[59]	_	_
11-11	1100-1109	signaling	abstract[59]	new[59]	_	_
11-12	1110-1113	and	_	_	_	_
11-13	1114-1124	resistance	abstract[60]	new[60]	_	_
11-14	1125-1127	to	abstract[60]	new[60]	_	_
11-15	1128-1134	fungus	abstract[60]|animal	new[60]|new	_	_
11-16	1135-1143	Botrytis	abstract[60]|abstract	new[60]|new	_	_
11-17	1144-1151	cinerea	abstract[60]	new[60]	_	_
11-18	1152-1153	,	_	_	_	_
11-19	1154-1156	is	_	_	_	_
11-20	1157-1166	dependent	_	_	_	_
11-21	1167-1169	on	_	_	_	_
11-22	1170-1173	the	event[63]	new[63]	coref	11-34[68_63]
11-23	1174-1185	interaction	event[63]	new[63]	_	_
11-24	1186-1193	between	event[63]	new[63]	_	_
11-25	1194-1199	MED25	event[63]|abstract|abstract[65]	new[63]|new|new[65]	_	_
11-26	1200-1207	subunit	event[63]|abstract[65]	new[63]|new[65]	_	_
11-27	1208-1210	of	event[63]|abstract[65]	new[63]|new[65]	_	_
11-28	1211-1214	the	event[63]|abstract[65]|person[66]	new[63]|new[65]|giv[66]	coref	11-39[71_66]
11-29	1215-1223	Mediator	event[63]|abstract[65]|person[66]	new[63]|new[65]|giv[66]	_	_
11-30	1224-1227	and	event[63]	new[63]	_	_
11-31	1228-1232	MYC2	event[63]|abstract	new[63]|new	_	_
11-32	1233-1234	,	event[63]	new[63]	_	_
11-33	1235-1238	and	event[63]	new[63]	_	_
11-34	1239-1250	interaction	event[63]|event[68]	new[63]|giv[68]	_	_
11-35	1251-1253	of	event[63]|event[68]	new[63]|giv[68]	_	_
11-36	1254-1258	MED8	event[63]|event[68]|abstract|organization[70]	new[63]|giv[68]|new|new[70]	_	_
11-37	1259-1266	subunit	event[63]|event[68]|organization[70]	new[63]|giv[68]|new[70]	_	_
11-38	1267-1269	of	event[63]|event[68]|organization[70]	new[63]|giv[68]|new[70]	_	_
11-39	1270-1273	the	event[63]|event[68]|organization[70]|person[71]	new[63]|giv[68]|new[70]|giv[71]	coref	14-14[95_71]
11-40	1274-1282	Mediator	event[63]|event[68]|organization[70]|person[71]	new[63]|giv[68]|new[70]|giv[71]	_	_
11-41	1283-1287	with	event[63]|event[68]	new[63]|giv[68]	_	_
11-42	1288-1292	FAMA	event[63]|event[68]|abstract[72]	new[63]|giv[68]|new[72]	_	_
11-43	1293-1302	belonging	event[63]|event[68]|abstract[72]	new[63]|giv[68]|new[72]	_	_
11-44	1303-1305	to	event[63]|event[68]|abstract[72]	new[63]|giv[68]|new[72]	_	_
11-45	1306-1309	the	event[63]|event[68]|abstract[72]|abstract[73]	new[63]|giv[68]|new[72]|giv[73]	_	_
11-46	1310-1314	bHLH	event[63]|event[68]|abstract[72]|abstract[73]	new[63]|giv[68]|new[72]|giv[73]	_	_
11-47	1315-1321	family	event[63]|event[68]|abstract[72]|abstract[73]	new[63]|giv[68]|new[72]|giv[73]	_	_
11-48	1322-1323	.	_	_	_	_

#Text=Sterol regulatory element binding proteins ( SREBPs )
12-1	1324-1330	Sterol	abstract|abstract[75]|substance[76]	new|giv[75]|giv[76]	coref	27-4[195_76]
12-2	1331-1341	regulatory	abstract[75]|substance[76]	giv[75]|giv[76]	_	_
12-3	1342-1349	element	abstract[75]|substance[76]	giv[75]|giv[76]	_	_
12-4	1350-1357	binding	substance[76]	giv[76]	_	_
12-5	1358-1366	proteins	substance[76]	giv[76]	_	_
12-6	1367-1368	(	_	_	_	_
12-7	1369-1375	SREBPs	abstract	new	coref	14-5[90_0]
12-8	1376-1377	)	_	_	_	_

#Text=the class II bHLH TFs ( Table 1 ) are transcription activators critical for regulation of cholesterol and fatty acid homeostasis in animals .
13-1	1378-1381	the	abstract[80]	new[80]	appos	13-7[81_80]
13-2	1382-1387	class	abstract[78]|abstract[80]	new[78]|new[80]	coref	16-4[104_78]
13-3	1388-1390	II	abstract[78]|abstract[80]	new[78]|new[80]	_	_
13-4	1391-1395	bHLH	substance|abstract[80]	giv|new[80]	coref	33-11
13-5	1396-1399	TFs	abstract[80]	new[80]	_	_
13-6	1400-1401	(	_	_	_	_
13-7	1402-1407	Table	abstract[81]	giv[81]	coref	13-11[83_81]
13-8	1408-1409	1	abstract[81]	giv[81]	_	_
13-9	1410-1411	)	_	_	_	_
13-10	1412-1415	are	_	_	_	_
13-11	1416-1429	transcription	abstract|abstract[83]	giv|giv[83]	coref|coref	16-6[0_83]|28-6
13-12	1430-1440	activators	abstract[83]	giv[83]	_	_
13-13	1441-1449	critical	abstract[83]	giv[83]	_	_
13-14	1450-1453	for	_	_	_	_
13-15	1454-1464	regulation	abstract[84]	new[84]	_	_
13-16	1465-1467	of	abstract[84]	new[84]	_	_
13-17	1468-1479	cholesterol	abstract[84]|substance|abstract[87]	new[84]|new|new[87]	ana	14-1[0_87]
13-18	1480-1483	and	abstract[84]|abstract[87]	new[84]|new[87]	_	_
13-19	1484-1489	fatty	abstract[84]|substance[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
13-20	1490-1494	acid	abstract[84]|substance[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
13-21	1495-1506	homeostasis	abstract[84]|abstract[87]	new[84]|new[87]	_	_
13-22	1507-1509	in	abstract[84]|abstract[87]	new[84]|new[87]	_	_
13-23	1510-1517	animals	abstract[84]|abstract[87]|animal	new[84]|new[87]|new	_	_
13-24	1518-1519	.	_	_	_	_

#Text=It was shown that human SREBPs bind CBP/p300 acetyltransferase and MED15 subunit of the Mediator to activate target genes .
14-1	1520-1522	It	abstract	giv	_	_
14-2	1523-1526	was	_	_	_	_
14-3	1527-1532	shown	_	_	_	_
14-4	1533-1537	that	_	_	_	_
14-5	1538-1543	human	abstract[90]	giv[90]	_	_
14-6	1544-1550	SREBPs	abstract[90]	giv[90]	_	_
14-7	1551-1555	bind	_	_	_	_
14-8	1556-1564	CBP/p300	abstract|place[92]	new|new[92]	coref|coref	19-4|19-4[129_92]
14-9	1565-1582	acetyltransferase	place[92]	new[92]	_	_
14-10	1583-1586	and	_	_	_	_
14-11	1587-1592	MED15	time|abstract[94]	new|new[94]	coref	15-8
14-12	1593-1600	subunit	abstract[94]	new[94]	_	_
14-13	1601-1603	of	abstract[94]	new[94]	_	_
14-14	1604-1607	the	abstract[94]|person[95]	new[94]|giv[95]	coref	15-12[0_95]
14-15	1608-1616	Mediator	abstract[94]|person[95]	new[94]|giv[95]	_	_
14-16	1617-1619	to	_	_	_	_
14-17	1620-1628	activate	_	_	_	_
14-18	1629-1635	target	abstract[96]	giv[96]	_	_
14-19	1636-1641	genes	abstract[96]	giv[96]	_	_
14-20	1642-1643	.	_	_	_	_

#Text=Also yeast Ino2 was shown to bind MED15 subunit of the Mediator tail .
15-1	1644-1648	Also	_	_	_	_
15-2	1649-1654	yeast	animal|abstract[98]	new|new[98]	_	_
15-3	1655-1659	Ino2	abstract[98]	new[98]	_	_
15-4	1660-1663	was	_	_	_	_
15-5	1664-1669	shown	_	_	_	_
15-6	1670-1672	to	_	_	_	_
15-7	1673-1677	bind	_	_	_	_
15-8	1678-1683	MED15	time|abstract[100]	giv|new[100]	_	_
15-9	1684-1691	subunit	abstract[100]	new[100]	_	_
15-10	1692-1694	of	abstract[100]	new[100]	_	_
15-11	1695-1698	the	abstract[100]|object[102]	new[100]|new[102]	_	_
15-12	1699-1707	Mediator	abstract[100]|person|object[102]	new[100]|giv|new[102]	_	_
15-13	1708-1712	tail	abstract[100]|object[102]	new[100]|new[102]	_	_
15-14	1713-1714	.	_	_	_	_

#Text=The representative of class II TFs TAL1 ( Table 1 ) is required for the specification of the blood lineage and maturation of several hematopoietic cells .
16-1	1715-1718	The	person[103]	new[103]	_	_
16-2	1719-1733	representative	person[103]	new[103]	_	_
16-3	1734-1736	of	person[103]	new[103]	_	_
16-4	1737-1742	class	person[103]|abstract[104]|abstract[106]	new[103]|giv[104]|new[106]	coref	19-1[0_106]
16-5	1743-1745	II	person[103]|abstract[104]|abstract[106]	new[103]|giv[104]|new[106]	_	_
16-6	1746-1749	TFs	person[103]|abstract|abstract[106]	new[103]|giv|new[106]	coref	16-9[107_0]
16-7	1750-1754	TAL1	person[103]|abstract[106]	new[103]|new[106]	_	_
16-8	1755-1756	(	_	_	_	_
16-9	1757-1762	Table	abstract[107]	giv[107]	coref	22-6[146_107]
16-10	1763-1764	1	abstract[107]	giv[107]	_	_
16-11	1765-1766	)	_	_	_	_
16-12	1767-1769	is	_	_	_	_
16-13	1770-1778	required	_	_	_	_
16-14	1779-1782	for	_	_	_	_
16-15	1783-1786	the	abstract[108]	new[108]	_	_
16-16	1787-1800	specification	abstract[108]	new[108]	_	_
16-17	1801-1803	of	abstract[108]	new[108]	_	_
16-18	1804-1807	the	abstract[108]|abstract[110]	new[108]|new[110]	_	_
16-19	1808-1813	blood	abstract[108]|substance|abstract[110]	new[108]|new|new[110]	_	_
16-20	1814-1821	lineage	abstract[108]|abstract[110]	new[108]|new[110]	_	_
16-21	1822-1825	and	abstract[108]	new[108]	_	_
16-22	1826-1836	maturation	abstract[108]|abstract[111]	new[108]|new[111]	_	_
16-23	1837-1839	of	abstract[108]|abstract[111]	new[108]|new[111]	_	_
16-24	1840-1847	several	abstract[108]|abstract[111]|animal[112]	new[108]|new[111]|new[112]	coref	17-16[120_112]
16-25	1848-1861	hematopoietic	abstract[108]|abstract[111]|animal[112]	new[108]|new[111]|new[112]	_	_
16-26	1862-1867	cells	abstract[108]|abstract[111]|animal[112]	new[108]|new[111]|new[112]	_	_
16-27	1868-1869	.	_	_	_	_

#Text=TAL1/SCL is considered as a master TF delineating the cell fate and the identity of progenitor and normal hematopoietic stem cells ( HSCs ) .
17-1	1870-1878	TAL1/SCL	abstract	new	_	_
17-2	1879-1881	is	_	_	_	_
17-3	1882-1892	considered	_	_	_	_
17-4	1893-1895	as	_	_	_	_
17-5	1896-1897	a	abstract[114]	new[114]	_	_
17-6	1898-1904	master	abstract[114]	new[114]	_	_
17-7	1905-1907	TF	abstract[114]	new[114]	_	_
17-8	1908-1919	delineating	abstract[114]	new[114]	_	_
17-9	1920-1923	the	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-10	1924-1928	cell	abstract[114]|place|abstract[116]	new[114]|giv|new[116]	coref	18-11
17-11	1929-1933	fate	abstract[114]|abstract[116]	new[114]|new[116]	_	_
17-12	1934-1937	and	abstract[114]	new[114]	_	_
17-13	1938-1941	the	abstract[114]|abstract[117]	new[114]|new[117]	ana	18-1[0_117]
17-14	1942-1950	identity	abstract[114]|abstract[117]	new[114]|new[117]	_	_
17-15	1951-1953	of	abstract[114]|abstract[117]	new[114]|new[117]	_	_
17-16	1954-1964	progenitor	abstract[114]|abstract[117]|animal|animal[120]	new[114]|new[117]|new|giv[120]	_	_
17-17	1965-1968	and	abstract[114]|abstract[117]|animal[120]	new[114]|new[117]|giv[120]	_	_
17-18	1969-1975	normal	abstract[114]|abstract[117]|animal[120]	new[114]|new[117]|giv[120]	_	_
17-19	1976-1989	hematopoietic	abstract[114]|abstract[117]|animal[120]	new[114]|new[117]|giv[120]	_	_
17-20	1990-1994	stem	abstract[114]|abstract[117]|plant|animal[120]	new[114]|new[117]|new|giv[120]	_	_
17-21	1995-2000	cells	abstract[114]|abstract[117]|animal[120]	new[114]|new[117]|giv[120]	_	_
17-22	2001-2002	(	_	_	_	_
17-23	2003-2007	HSCs	abstract	new	_	_
17-24	2008-2009	)	_	_	_	_
17-25	2010-2011	.	_	_	_	_

#Text=It regulates other hematopoietic TFs thus has a potential for cell reprogramming .
18-1	2012-2014	It	abstract	giv	_	_
18-2	2015-2024	regulates	_	_	_	_
18-3	2025-2030	other	abstract[123]	new[123]	coref	22-25[153_123]
18-4	2031-2044	hematopoietic	abstract[123]	new[123]	_	_
18-5	2045-2048	TFs	abstract[123]	new[123]	_	_
18-6	2049-2053	thus	_	_	_	_
18-7	2054-2057	has	_	_	_	_
18-8	2058-2059	a	abstract[124]	new[124]	_	_
18-9	2060-2069	potential	abstract[124]	new[124]	_	_
18-10	2070-2073	for	abstract[124]	new[124]	_	_
18-11	2074-2078	cell	abstract[124]|place|event[126]	new[124]|giv|new[126]	coref	24-2[163_0]
18-12	2079-2092	reprogramming	abstract[124]|event[126]	new[124]|new[126]	_	_
18-13	2093-2094	.	_	_	_	_

#Text=TAL1 also binds CBP/p300 acetyltransferase .
19-1	2095-2099	TAL1	abstract	giv	_	_
19-2	2100-2104	also	_	_	_	_
19-3	2105-2110	binds	_	_	_	_
19-4	2111-2119	CBP/p300	abstract|place[129]	giv|giv[129]	coref	20-17[136_129]
19-5	2120-2137	acetyltransferase	place[129]	giv[129]	_	_
19-6	2138-2139	.	_	_	_	_

#Text=Similarly MyoD — a myogenic regulatory factor which controls skeletal muscle development binds CBP and recruits histone acetyltransferase to activate myogenic program .
20-1	2140-2149	Similarly	_	_	_	_
20-2	2150-2154	MyoD	abstract	new	appos	20-4[131_0]
20-3	2155-2156	—	_	_	_	_
20-4	2157-2158	a	abstract[131]	giv[131]	coref	21-7[0_131]
20-5	2159-2167	myogenic	abstract[131]	giv[131]	_	_
20-6	2168-2178	regulatory	abstract[131]	giv[131]	_	_
20-7	2179-2185	factor	abstract[131]	giv[131]	_	_
20-8	2186-2191	which	abstract[131]	giv[131]	_	_
20-9	2192-2200	controls	abstract[131]	giv[131]	_	_
20-10	2201-2209	skeletal	abstract[131]|object[132]|event[133]	giv[131]|new[132]|new[133]	_	_
20-11	2210-2216	muscle	abstract[131]|object[132]|event[133]	giv[131]|new[132]|new[133]	_	_
20-12	2217-2228	development	abstract[131]|event[133]	giv[131]|new[133]	_	_
20-13	2229-2234	binds	_	_	_	_
20-14	2235-2238	CBP	abstract	new	_	_
20-15	2239-2242	and	_	_	_	_
20-16	2243-2251	recruits	_	_	_	_
20-17	2252-2259	histone	animal|place[136]	giv|giv[136]	coref|coref	25-19|25-19[185_136]
20-18	2260-2277	acetyltransferase	place[136]	giv[136]	_	_
20-19	2278-2280	to	_	_	_	_
20-20	2281-2289	activate	_	_	_	_
20-21	2290-2298	myogenic	abstract[137]	new[137]	_	_
20-22	2299-2306	program	abstract[137]	new[137]	_	_
20-23	2307-2308	.	_	_	_	_

#Text=Cao et al. showed that of MyoD modify the myoblasts chromatin structure and accessibility .
21-1	2309-2312	Cao	person	new	_	_
21-2	2313-2315	et	_	_	_	_
21-3	2316-2319	al.	_	_	_	_
21-4	2320-2326	showed	_	_	_	_
21-5	2327-2331	that	_	_	_	_
21-6	2332-2334	of	_	_	_	_
21-7	2335-2339	MyoD	abstract	giv	coref	22-13[148_0]
21-8	2340-2346	modify	_	_	_	_
21-9	2347-2350	the	abstract[142]	new[142]	_	_
21-10	2351-2360	myoblasts	animal|abstract[142]	new|new[142]	_	_
21-11	2361-2370	chromatin	abstract|abstract[142]	new|new[142]	coref	22-18
21-12	2371-2380	structure	abstract[142]	new[142]	_	_
21-13	2381-2384	and	_	_	_	_
21-14	2385-2398	accessibility	abstract	new	coref	22-18[150_0]
21-15	2399-2400	.	_	_	_	_

#Text=ASCL1 ( class II , Table 1 ) was shown to be a pioneer factor which promotes chromatin accessibility and enables chromatin binding by others TFs .
22-1	2401-2406	ASCL1	abstract	new	appos	22-3[145_0]
22-2	2407-2408	(	_	_	_	_
22-3	2409-2414	class	abstract[145]	giv[145]	coref	27-8[197_145]
22-4	2415-2417	II	abstract[145]	giv[145]	_	_
22-5	2418-2419	,	_	_	_	_
22-6	2420-2425	Table	abstract[146]	giv[146]	coref	23-8[156_146]
22-7	2426-2427	1	abstract[146]	giv[146]	_	_
22-8	2428-2429	)	_	_	_	_
22-9	2430-2433	was	_	_	_	_
22-10	2434-2439	shown	_	_	_	_
22-11	2440-2442	to	_	_	_	_
22-12	2443-2445	be	_	_	_	_
22-13	2446-2447	a	abstract[148]	giv[148]	coref	23-15[158_148]
22-14	2448-2455	pioneer	person|abstract[148]	new|giv[148]	coref	23-16
22-15	2456-2462	factor	abstract[148]	giv[148]	_	_
22-16	2463-2468	which	abstract[148]	giv[148]	_	_
22-17	2469-2477	promotes	abstract[148]	giv[148]	_	_
22-18	2478-2487	chromatin	abstract[148]|abstract|abstract[150]	giv[148]|giv|giv[150]	coref	22-22
22-19	2488-2501	accessibility	abstract[148]|abstract[150]	giv[148]|giv[150]	_	_
22-20	2502-2505	and	abstract[148]	giv[148]	_	_
22-21	2506-2513	enables	abstract[148]	giv[148]	_	_
22-22	2514-2523	chromatin	abstract[148]|abstract|event[152]	giv[148]|giv|new[152]	coref	31-3[0_152]
22-23	2524-2531	binding	abstract[148]|event[152]	giv[148]|new[152]	_	_
22-24	2532-2534	by	abstract[148]|event[152]	giv[148]|new[152]	_	_
22-25	2535-2541	others	abstract[148]|event[152]|abstract[153]	giv[148]|new[152]|giv[153]	coref	29-14[207_153]
22-26	2542-2545	TFs	abstract[148]|event[152]|abstract[153]	giv[148]|new[152]|giv[153]	_	_
22-27	2546-2547	.	_	_	_	_

#Text=Recently , also AHR ( bHLH-PAS , Table 1 ) was suggested to be a pioneer factor which regulates DNA methylation during embryonic developments in unknown way .
23-1	2548-2556	Recently	_	_	_	_
23-2	2557-2558	,	_	_	_	_
23-3	2559-2563	also	_	_	_	_
23-4	2564-2567	AHR	abstract	new	_	_
23-5	2568-2569	(	_	_	_	_
23-6	2570-2578	bHLH-PAS	substance	new	coref	25-13
23-7	2579-2580	,	_	_	_	_
23-8	2581-2586	Table	abstract[156]	giv[156]	coref	25-15[183_156]
23-9	2587-2588	1	abstract[156]	giv[156]	_	_
23-10	2589-2590	)	_	_	_	_
23-11	2591-2594	was	_	_	_	_
23-12	2595-2604	suggested	_	_	_	_
23-13	2605-2607	to	_	_	_	_
23-14	2608-2610	be	_	_	_	_
23-15	2611-2612	a	abstract[158]	giv[158]	coref	32-28[232_158]
23-16	2613-2620	pioneer	person|abstract[158]	giv|giv[158]	_	_
23-17	2621-2627	factor	abstract[158]	giv[158]	_	_
23-18	2628-2633	which	abstract[158]	giv[158]	_	_
23-19	2634-2643	regulates	abstract[158]	giv[158]	_	_
23-20	2644-2647	DNA	abstract[158]|abstract|abstract[160]	giv[158]|new|new[160]	coref	29-7
23-21	2648-2659	methylation	abstract[158]|abstract[160]	giv[158]|new[160]	_	_
23-22	2660-2666	during	abstract[158]	giv[158]	_	_
23-23	2667-2676	embryonic	abstract[158]|event[161]	giv[158]|new[161]	_	_
23-24	2677-2689	developments	abstract[158]|event[161]	giv[158]|new[161]	_	_
23-25	2690-2692	in	abstract[158]	giv[158]	_	_
23-26	2693-2700	unknown	abstract[158]|abstract[162]	giv[158]|new[162]	coref	30-13[211_162]
23-27	2701-2704	way	abstract[158]|abstract[162]	giv[158]|new[162]	_	_
23-28	2705-2706	.	_	_	_	_

#Text=In clear cell renal cell carcinoma ( ccRCC ) , the most frequent mutation causes the von Hippel-Lindau ( VHL ) tumor suppressor inactivation leading to genome-wide enhancer and super-enhancer remodeling .
24-1	2707-2709	In	_	_	_	_
24-2	2710-2715	clear	place[163]|object[166]	giv[163]|new[166]	coref	24-4[165_163]
24-3	2716-2720	cell	place[163]|object[166]	giv[163]|new[166]	_	_
24-4	2721-2726	renal	abstract|place[165]|object[166]	new|giv[165]|new[166]	coref	33-23[0_165]
24-5	2727-2731	cell	place[165]|object[166]	giv[165]|new[166]	_	_
24-6	2732-2741	carcinoma	object[166]	new[166]	_	_
24-7	2742-2743	(	_	_	_	_
24-8	2744-2749	ccRCC	abstract	new	_	_
24-9	2750-2751	)	_	_	_	_
24-10	2752-2753	,	_	_	_	_
24-11	2754-2757	the	abstract[168]	new[168]	_	_
24-12	2758-2762	most	abstract[168]	new[168]	_	_
24-13	2763-2771	frequent	abstract[168]	new[168]	_	_
24-14	2772-2780	mutation	abstract[168]	new[168]	_	_
24-15	2781-2787	causes	_	_	_	_
24-16	2788-2791	the	event[174]	new[174]	_	_
24-17	2792-2795	von	person|abstract[170]|event[174]	new|new[170]|new[174]	appos	24-20[0_170]
24-18	2796-2809	Hippel-Lindau	abstract[170]|event[174]	new[170]|new[174]	_	_
24-19	2810-2811	(	event[174]	new[174]	_	_
24-20	2812-2815	VHL	abstract|event[174]	giv|new[174]	_	_
24-21	2816-2817	)	event[174]	new[174]	_	_
24-22	2818-2823	tumor	object|object[173]|event[174]	new|new[173]|new[174]	_	_
24-23	2824-2834	suppressor	object[173]|event[174]	new[173]|new[174]	_	_
24-24	2835-2847	inactivation	event[174]	new[174]	_	_
24-25	2848-2855	leading	event[174]	new[174]	_	_
24-26	2856-2858	to	event[174]	new[174]	_	_
24-27	2859-2870	genome-wide	event[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
24-28	2871-2879	enhancer	event[174]|abstract[175]|abstract[177]	new[174]|new[175]|giv[177]	_	_
24-29	2880-2883	and	event[174]|abstract[177]	new[174]|giv[177]	_	_
24-30	2884-2898	super-enhancer	event[174]|abstract|abstract[177]	new[174]|new|giv[177]	_	_
24-31	2899-2909	remodeling	event[174]|abstract[177]	new[174]|giv[177]	_	_
24-32	2910-2911	.	_	_	_	_

#Text=This process is mediated by the interaction of HIF2α and HIF1β ( bHLH-PAS , Table 1 ) with histone acetyltransferase p300 .
25-1	2912-2916	This	event[178]	new[178]	_	_
25-2	2917-2924	process	event[178]	new[178]	_	_
25-3	2925-2927	is	_	_	_	_
25-4	2928-2936	mediated	_	_	_	_
25-5	2937-2939	by	_	_	_	_
25-6	2940-2943	the	event[179]	new[179]	_	_
25-7	2944-2955	interaction	event[179]	new[179]	_	_
25-8	2956-2958	of	event[179]	new[179]	_	_
25-9	2959-2964	HIF2α	event[179]|abstract	new[179]|new	_	_
25-10	2965-2968	and	event[179]	new[179]	_	_
25-11	2969-2974	HIF1β	event[179]|abstract	new[179]|new	_	_
25-12	2975-2976	(	event[179]	new[179]	_	_
25-13	2977-2985	bHLH-PAS	event[179]|substance	new[179]|giv	coref	26-5
25-14	2986-2987	,	event[179]	new[179]	_	_
25-15	2988-2993	Table	event[179]|abstract[183]	new[179]|giv[183]	coref	26-9[190_183]
25-16	2994-2995	1	event[179]|abstract[183]	new[179]|giv[183]	_	_
25-17	2996-2997	)	event[179]	new[179]	_	_
25-18	2998-3002	with	event[179]	new[179]	_	_
25-19	3003-3010	histone	event[179]|animal|place[185]	new[179]|giv|giv[185]	coref	26-16
25-20	3011-3028	acetyltransferase	event[179]|place[185]	new[179]|giv[185]	_	_
25-21	3029-3033	p300	event[179]|place[185]	new[179]|giv[185]	_	_
25-22	3034-3035	.	_	_	_	_

#Text=CLOCK , the other bHLH-PAS subfamily member ( Table 1 ) was shown to mediate histone acetylation in a circadian time-specific manner .
26-1	3036-3041	CLOCK	object	new	_	_
26-2	3042-3043	,	_	_	_	_
26-3	3044-3047	the	person[189]	new[189]	coref	27-1[196_189]
26-4	3048-3053	other	person[189]	new[189]	_	_
26-5	3054-3062	bHLH-PAS	substance|person[189]	giv|new[189]	_	_
26-6	3063-3072	subfamily	abstract|person[189]	new|new[189]	_	_
26-7	3073-3079	member	person[189]	new[189]	_	_
26-8	3080-3081	(	_	_	_	_
26-9	3082-3087	Table	abstract[190]	giv[190]	coref	28-11[202_190]
26-10	3088-3089	1	abstract[190]	giv[190]	_	_
26-11	3090-3091	)	_	_	_	_
26-12	3092-3095	was	_	_	_	_
26-13	3096-3101	shown	_	_	_	_
26-14	3102-3104	to	_	_	_	_
26-15	3105-3112	mediate	_	_	_	_
26-16	3113-3120	histone	animal|substance[192]	giv|new[192]	coref	29-11
26-17	3121-3132	acetylation	substance[192]	new[192]	_	_
26-18	3133-3135	in	_	_	_	_
26-19	3136-3137	a	abstract[193]	new[193]	_	_
26-20	3138-3147	circadian	abstract[193]	new[193]	_	_
26-21	3148-3161	time-specific	abstract[193]	new[193]	_	_
26-22	3162-3168	manner	abstract[193]	new[193]	_	_
26-23	3169-3170	.	_	_	_	_

#Text=Interestingly , the bHLH-O proteins members ( class VI , Table 1 )
27-1	3171-3184	Interestingly	person[196]	giv[196]	ana	29-1[0_196]
27-2	3185-3186	,	person[196]	giv[196]	_	_
27-3	3187-3190	the	person[196]	giv[196]	_	_
27-4	3191-3197	bHLH-O	abstract|substance[195]|person[196]	new|giv[195]|giv[196]	coref	28-2[0_195]
27-5	3198-3206	proteins	substance[195]|person[196]	giv[195]|giv[196]	_	_
27-6	3207-3214	members	person[196]	giv[196]	_	_
27-7	3215-3216	(	_	_	_	_
27-8	3217-3222	class	abstract[197]	giv[197]	_	_
27-9	3223-3225	VI	abstract[197]	giv[197]	_	_
27-10	3226-3227	,	_	_	_	_
27-11	3228-3233	Table	_	_	_	_
27-12	3234-3235	1	_	_	_	_
27-13	3236-3237	)	_	_	_	_

#Text=HEY proteins can function as transcription repressors as well as transcription activators .
28-1	3238-3241	HEY	_	_	_	_
28-2	3242-3250	proteins	substance	giv	coref	33-10[236_0]
28-3	3251-3254	can	_	_	_	_
28-4	3255-3263	function	_	_	_	_
28-5	3264-3266	as	_	_	_	_
28-6	3267-3280	transcription	abstract|abstract[200]	giv|new[200]	coref	28-11
28-7	3281-3291	repressors	abstract[200]	new[200]	_	_
28-8	3292-3294	as	_	_	_	_
28-9	3295-3299	well	_	_	_	_
28-10	3300-3302	as	_	_	_	_
28-11	3303-3316	transcription	abstract|abstract[202]	giv|giv[202]	coref|coref	32-8|32-16[227_202]
28-12	3317-3327	activators	abstract[202]	giv[202]	_	_
28-13	3328-3329	.	_	_	_	_

#Text=They were shown to bind directly DNA and interact with histone deacetylases and other TFs .
29-1	3330-3334	They	person	giv	_	_
29-2	3335-3339	were	_	_	_	_
29-3	3340-3345	shown	_	_	_	_
29-4	3346-3348	to	_	_	_	_
29-5	3349-3353	bind	_	_	_	_
29-6	3354-3362	directly	_	_	_	_
29-7	3363-3366	DNA	abstract	giv	_	_
29-8	3367-3370	and	_	_	_	_
29-9	3371-3379	interact	_	_	_	_
29-10	3380-3384	with	_	_	_	_
29-11	3385-3392	histone	animal|substance[206]	giv|new[206]	_	_
29-12	3393-3405	deacetylases	substance[206]	new[206]	_	_
29-13	3406-3409	and	_	_	_	_
29-14	3410-3415	other	abstract[207]	giv[207]	coref	32-4[222_207]
29-15	3416-3419	TFs	abstract[207]	giv[207]	_	_
29-16	3420-3421	.	_	_	_	_

#Text=On the other hand , gene activation by HEY is regulated in an indirect way .
30-1	3422-3424	On	_	_	_	_
30-2	3425-3428	the	_	_	_	_
30-3	3429-3434	other	_	_	_	_
30-4	3435-3439	hand	_	_	_	_
30-5	3440-3441	,	_	_	_	_
30-6	3442-3446	gene	abstract|event[209]	new|new[209]	_	_
30-7	3447-3457	activation	event[209]	new[209]	_	_
30-8	3458-3460	by	event[209]	new[209]	_	_
30-9	3461-3464	HEY	event[209]|abstract	new[209]|new	coref	31-2
30-10	3465-3467	is	_	_	_	_
30-11	3468-3477	regulated	_	_	_	_
30-12	3478-3480	in	_	_	_	_
30-13	3481-3483	an	abstract[211]	giv[211]	_	_
30-14	3484-3492	indirect	abstract[211]	giv[211]	_	_
30-15	3493-3496	way	abstract[211]	giv[211]	_	_
30-16	3497-3498	.	_	_	_	_

#Text=Multiple HEY binding sites located downstream and close to the transcriptional start site , resulted in a hypothesis that HEY influence the pausing/elongation switch of Pol II .
31-1	3499-3507	Multiple	place[214]	new[214]	_	_
31-2	3508-3511	HEY	abstract|place[214]	giv|new[214]	coref	31-20
31-3	3512-3519	binding	event|place[214]	giv|new[214]	_	_
31-4	3520-3525	sites	place[214]	new[214]	_	_
31-5	3526-3533	located	place[214]	new[214]	_	_
31-6	3534-3544	downstream	place[214]	new[214]	_	_
31-7	3545-3548	and	place[214]	new[214]	_	_
31-8	3549-3554	close	place[214]	new[214]	_	_
31-9	3555-3557	to	place[214]	new[214]	_	_
31-10	3558-3561	the	place[214]|place[216]	new[214]|new[216]	_	_
31-11	3562-3577	transcriptional	place[214]|place[216]	new[214]|new[216]	_	_
31-12	3578-3583	start	place[214]|event|place[216]	new[214]|new|new[216]	_	_
31-13	3584-3588	site	place[214]|place[216]	new[214]|new[216]	_	_
31-14	3589-3590	,	_	_	_	_
31-15	3591-3599	resulted	_	_	_	_
31-16	3600-3602	in	_	_	_	_
31-17	3603-3604	a	abstract[217]	new[217]	_	_
31-18	3605-3615	hypothesis	abstract[217]	new[217]	_	_
31-19	3616-3620	that	abstract[217]	new[217]	_	_
31-20	3621-3624	HEY	abstract[217]|abstract	new[217]|giv	_	_
31-21	3625-3634	influence	abstract[217]	new[217]	_	_
31-22	3635-3638	the	abstract[217]|event[220]	new[217]|new[220]	_	_
31-23	3639-3657	pausing/elongation	abstract[217]|event|event[220]	new[217]|new|new[220]	_	_
31-24	3658-3664	switch	abstract[217]|event[220]	new[217]|new[220]	_	_
31-25	3665-3667	of	abstract[217]|event[220]	new[217]|new[220]	_	_
31-26	3668-3671	Pol	abstract[217]|event[220]|person[221]	new[217]|new[220]|giv[221]	_	_
31-27	3672-3674	II	abstract[217]|event[220]|person[221]	new[217]|new[220]|giv[221]	_	_
31-28	3675-3676	.	_	_	_	_

#Text=Interestingly , though most of TFs stimulate transcription initiation , MYC ( class III , Table 1 ) was shown to stimulate transcription elongation by recruitment of the elongation factor .
32-1	3677-3690	Interestingly	_	_	_	_
32-2	3691-3692	,	_	_	_	_
32-3	3693-3699	though	_	_	_	_
32-4	3700-3704	most	abstract[222]	giv[222]	_	_
32-5	3705-3707	of	abstract[222]	giv[222]	_	_
32-6	3708-3711	TFs	abstract[222]	giv[222]	_	_
32-7	3712-3721	stimulate	_	_	_	_
32-8	3722-3735	transcription	abstract|event[224]	giv|new[224]	coref	32-23
32-9	3736-3746	initiation	event[224]	new[224]	_	_
32-10	3747-3748	,	_	_	_	_
32-11	3749-3752	MYC	abstract	new	appos	32-13[226_0]
32-12	3753-3754	(	_	_	_	_
32-13	3755-3760	class	abstract[226]	giv[226]	_	_
32-14	3761-3764	III	abstract[226]	giv[226]	_	_
32-15	3765-3766	,	_	_	_	_
32-16	3767-3772	Table	abstract[227]	giv[227]	_	_
32-17	3773-3774	1	abstract[227]	giv[227]	_	_
32-18	3775-3776	)	_	_	_	_
32-19	3777-3780	was	_	_	_	_
32-20	3781-3786	shown	_	_	_	_
32-21	3787-3789	to	_	_	_	_
32-22	3790-3799	stimulate	_	_	_	_
32-23	3800-3813	transcription	abstract|abstract[229]	giv|new[229]	coref	32-29[0_229]
32-24	3814-3824	elongation	abstract[229]	new[229]	_	_
32-25	3825-3827	by	_	_	_	_
32-26	3828-3839	recruitment	event[230]	new[230]	_	_
32-27	3840-3842	of	event[230]	new[230]	_	_
32-28	3843-3846	the	event[230]|abstract[232]	new[230]|giv[232]	_	_
32-29	3847-3857	elongation	event[230]|abstract|abstract[232]	new[230]|giv|giv[232]	_	_
32-30	3858-3864	factor	event[230]|abstract[232]	new[230]|giv[232]	_	_
32-31	3865-3866	.	_	_	_	_

#Text=The presented studies indicate that the crucial role of the bHLH proteins in maintaining transcriptional regulation of important developmental ( e.g. , cell differentiation ) and oncogenic pathways is dependent on the multiple interactions with basal transcriptional machinery .
33-1	3867-3870	The	abstract[233]	new[233]	_	_
33-2	3871-3880	presented	abstract[233]	new[233]	_	_
33-3	3881-3888	studies	abstract[233]	new[233]	_	_
33-4	3889-3897	indicate	_	_	_	_
33-5	3898-3902	that	_	_	_	_
33-6	3903-3906	the	abstract[234]	new[234]	_	_
33-7	3907-3914	crucial	abstract[234]	new[234]	_	_
33-8	3915-3919	role	abstract[234]	new[234]	_	_
33-9	3920-3922	of	abstract[234]	new[234]	_	_
33-10	3923-3926	the	abstract[234]|substance[236]	new[234]|giv[236]	_	_
33-11	3927-3931	bHLH	abstract[234]|substance|substance[236]	new[234]|giv|giv[236]	_	_
33-12	3932-3940	proteins	abstract[234]|substance[236]	new[234]|giv[236]	_	_
33-13	3941-3943	in	_	_	_	_
33-14	3944-3955	maintaining	_	_	_	_
33-15	3956-3971	transcriptional	abstract[237]	new[237]	_	_
33-16	3972-3982	regulation	abstract[237]	new[237]	_	_
33-17	3983-3985	of	abstract[237]	new[237]	_	_
33-18	3986-3995	important	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-19	3996-4009	developmental	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-20	4010-4011	(	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-21	4012-4016	e.g.	abstract[237]|abstract[239]|abstract[240]	new[237]|new[239]|new[240]	_	_
33-22	4017-4018	,	abstract[237]|abstract[239]|abstract[240]	new[237]|new[239]|new[240]	_	_
33-23	4019-4023	cell	abstract[237]|place|abstract[239]|abstract[240]	new[237]|giv|new[239]|new[240]	_	_
33-24	4024-4039	differentiation	abstract[237]|abstract[239]|abstract[240]	new[237]|new[239]|new[240]	_	_
33-25	4040-4041	)	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-26	4042-4045	and	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-27	4046-4055	oncogenic	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-28	4056-4064	pathways	abstract[237]|abstract[240]	new[237]|new[240]	_	_
33-29	4065-4067	is	_	_	_	_
33-30	4068-4077	dependent	_	_	_	_
33-31	4078-4080	on	_	_	_	_
33-32	4081-4084	the	abstract[241]	new[241]	_	_
33-33	4085-4093	multiple	abstract[241]	new[241]	_	_
33-34	4094-4106	interactions	abstract[241]	new[241]	_	_
33-35	4107-4111	with	abstract[241]	new[241]	_	_
33-36	4112-4117	basal	abstract[241]|object[242]	new[241]|new[242]	_	_
33-37	4118-4133	transcriptional	abstract[241]|object[242]	new[241]|new[242]	_	_
33-38	4134-4143	machinery	abstract[241]|object[242]	new[241]|new[242]	_	_
33-39	4144-4145	.	_	_	_	_
